Noramco

Executive Summary

Noramco is a leading specialty active pharmaceutical ingredient (API) development and manufacturing company, founded in 1979 and headquartered in Wilmington, Delaware. The company focuses on supporting the advancement of opioid and non-opioid products across a range of therapeutic applications, with a strong emphasis on pain management and controlled substances. With over four decades of experience, Noramco has established itself as a trusted partner for pharmaceutical companies requiring high-quality APIs, leveraging its expertise in small molecules and drug delivery technologies. The company operates globally, maintaining facilities that adhere to stringent regulatory standards, and continues to invest in innovation to address the evolving needs of the healthcare industry. Noramco's position as a private entity allows it to maintain a long-term strategic focus without the pressures of quarterly earnings, enabling sustained investment in research and development. The company's commitment to quality and reliability has made it a key player in the API supply chain, particularly for medications where purity and consistency are critical.

Upcoming Catalysts (preview)

• Q3 2027FDA Approval of New Non-Opioid Pain Management API40% success
• Q4 2026Completion of Manufacturing Capacity Expansion70% success
• Q2 2027Strategic Partnership for Advanced Drug Delivery Technologies50% success